Related Experiment Video

Updated: Jun 7, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Toward a pathway-centered approach for the treatment of adrenocortical carcinoma

Kimberly J Bussey1, Michael J Demeure

  • 1Clinical Translational Research Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.

Current Opinion in Oncology
|November 4, 2010
PubMed
Abstract

Insights

Adrenocortical carcinoma research reveals key molecular pathways for targeted therapy, focusing on cell cycle regulation and growth factor signaling. Further genomic analysis is crucial for advancing treatment strategies for this rare cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy of the adrenal cortex.
  • The disease's rarity has historically hindered therapeutic development.
  • Recent advancements in molecular pathogenesis have identified potential diagnostic and therapeutic targets.

Purpose of the Study:

  • To review recent molecular findings in adrenocortical carcinoma.
  • To identify key pathways for short-term and long-term therapeutic development.
  • To highlight the importance of understanding ACC heterogeneity for clinical application.

Main Methods:

  • Review of recent molecular characterization studies of adrenocortical carcinoma.
  • Analysis of gene-level heterogeneity and convergence onto common cellular pathways.
  • Investigation of signaling pathways including IGF-1R, Wnt, and BMP.

Main Results:

  • Dysregulation of the G2/mitosis transition and IGF-1R signaling are critical pathways for ACC therapy.
  • ACC exhibits significant gene-level heterogeneity that converges on common cellular processes.
  • Wnt/β-catenin, BMP signaling, and ERCC1 expression are implicated in ACC biology and treatment response.

Conclusions:

  • Short-term therapeutic strategies should focus on the G2/mitosis transition and IGF-1R signaling.
  • Long-term research requires deeper characterization of patient samples at the sequence level.
  • Understanding molecular complexities is essential for advancing clinical practice in ACC.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.